Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2.

Mya Myat Ngwe TunTakaya SakuraYasuteru SakuraiYohei KurosakiDaniel Ken InaokaNorifumi ShiodaJiro YasudaKiyoshi KitaKouichi Morita

Published in: Tropical medicine and health (2022)

Our study suggests that 5-ALA with SFC warrants accelerated clinical evaluation as an antiviral drug candidate for treating patients infected with SARS-CoV-2 variants.

Keyphrases

respiratory syndrome coronavirus
sars cov
clinical evaluation
end stage renal disease
copy number
ejection fraction
newly diagnosed
chronic kidney disease
coronavirus disease
photodynamic therapy
peritoneal dialysis
prognostic factors
gene expression
patient reported
genome wide
drug induced